At a glance
This site provides information on the independent peer review of documents defined by ÐÇ¿ÕÓéÀÖ¹ÙÍø as influential in terms of their potential impact on public policy or the private sector. ÐÇ¿ÕÓéÀÖ¹ÙÍø makes this information available to demonstrate its efforts to utilize only the most transparent and independent peer review, appropriate research methods, and the highest level of data quality.
Purpose
In addition, this information demonstrates ÐÇ¿ÕÓéÀÖ¹ÙÍø compliance with the specific requirements of the , and of peer review standards developed by the Office of Management and Budget (OMB), Department of Health and Human Services (DHHS), and Centers for Disease Control and Prevention (ÐÇ¿ÕÓéÀÖ¹ÙÍø). OMB requirements, described in the Peer Review Bulletin, include making publicly available specific information on the peer review of influential documents disseminated by the federal government. OMB has defined two special categories of influential information, Influential Scientific Information (ISI) and Highly Influential Scientific Assessments (HISAs).
For issues related to the ÐÇ¿ÕÓéÀÖ¹ÙÍø/ATSDR Peer Review Agenda please contact:
Information Quality Peer Review Staff
Centers for Disease Control and Prevention
Office of Science Quality
1600 Clifton Road, NE MS D-72
Atlanta, GA 30333
The following HISAs and ISI are under development or published in final form:
Highly Influential Scientific Assessments (HISA)
NIOSH
- Draft NIOSH Criteria for a Recommended Standard: Occupational Exposure to Toluene diisocyanate
- NIOSH Criteria for a Recommended Standard: 1-Bromopropane
- NIOSH Hazard Review Wildland Fire Smoke Exposure among Farmworkers and Other Outdoor Workers
- NIOSH Skin Notation Profile for 1-Bromopropane (CAS# 106-94-5)
- NIOSH Skin Notation Profile for 2-Hydropropyl acrylate (CAS# 999-61-1)
- NIOSH Skin Notation Profile for Arsenic (CAS# 7440-38-2)
- NIOSH Skin Notation Profile for Dimethyl sulfate (CAS# 77-78-1)
- NIOSH Skin Notation Profile for Dioxathion (CAS#78-34-2)
- NIOSH Skin Notation Profile for Disulfoton (CAS# 298-04-4)
- NIOSH Skin Notation Profile for Heptachlor (CAS# 76-44-8)
- NIOSH Skin Notation Profile for Tetraethyl lead (CAS# 78-00-2)
- NIOSH Skin Notation Profile for Tetramethyl lead (CAS# 75-74-1)
- NIOSH Skin Notation Profile for Trichloroethylene (CAS# 79-01-06)
- NIOSH List of Hazardous Drugs in Healthcare Settings 2024 (formerly titled NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2024)
Toxicological
Influential Scientific Information (ISI)
- A Vapor Containment Performance Protocol for Closed System Transfer Devices Used During Pharmacy Compounding and Administration of Hazardous Drugs
- Best Practices for Cardiovascular Disease Prevention Programs: A Guide to Effective Health Care System Interventions and Community Programs Linked to Clinical Services
- Draft NIOSH Technical Report: Approaches to Developing Occupational Exposure Limits or Bands for Engineered Nanomaterials
- Draft Skin Notation Profile: Chlorodiphenyl (42% chlorine)
- Draft Skin Notation Profile: Cyclohexanol
- Draft Skin Notation Profile: Cyclohexanone
- Draft Skin Notation Profile: Cyclonite
- Draft Skin Notation Profile: Diethylenetriamine
- Guidelines for the use of doxycycline post-exposure prophylaxis for bacterial sexually transmitted infection prevention
- Laboratory Recommendations for Syphilis Testing in the United States
- NNCSS Technical Report: Prevalence of Multiple Sclerosis: Methods and Prevalence Estimates by Age, Sex, and other Demographic and Geographic Characteristics among Adults Aged 18 and Older, United States
- Update on 3HP TB Peer Review Plan
- Official American Thoracic Society / Centers for Disease Control / Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
- NNCSS Technical Report: Prevalence of Parkinson's Disease: Methods and Prevalence Estimates by Age, Sex, and other Demographic and Geographic Characteristics among Adults Aged 35 and Older, United States
- Recommendations for Hepatitis B Screening and Testing
- Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children – United States, 2023
- Recommendations for specimen self-collection at home or in other nonclinical settings as an additional strategy for gonorrhea andchlamydia testing
- Recommendations for the Use of Specimens Collected At-Home or in Other Nonclinical Settings for Chlamydia trachomatis and Neisseria gonorrhoeae Testing
- Sexually Transmitted Infections Treatment Guidelines, 2021 (cdc.gov)
- STI Treatment Guidelines (cdc.gov)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
- U.S. Selected Practice Recommendations for Contraceptive Use, 2016
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024
Peer Review
- Peer Review Plan for Pediatric Mild Traumatic Brain Injury Guideline Report, 2017
- Peer Review Plan for the ÐÇ¿ÕÓéÀÖ¹ÙÍø Clinical Practice Guideline for Prescribing Opioids for Pain, 2022
- Peer Review Plan for the ÐÇ¿ÕÓéÀÖ¹ÙÍø Guideline for Prescribing Opioids for Chronic Pain, 2016
- Peer Review Plan for Recommendations for Hepatitis C Screening among Adults
Toxicological